The Eye Study

This condition can occur in people with diabetes, and it causes blood in the eye to leak from damaged vessels of the retina into the macula (the part of the eye that helps our vision to be clear and sharp).

As a result, patients with this condition can experience deterioration of their eyesight. The study drug is designed to specifically target inflammation in the eye and inhibit angiogenesis in neovascular ocular diseases such neovascular (wet) age-related macular degeneration (AMD) and diabetic macular oedema (DME).

Historically, these conditions have been treated with therapies that are injected directly into the vitreous (the gel that fills the space between the lens and the retina) of the eye. However, this study drug is administered via an injection into the upper outer thigh, which is a less invasive method of administration.

The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.

Call us on 1800 243 733 to discuss your eligibility today!